NICM
OCUL icon

Neo Ivy Capital Management’s Ocular Therapeutix OCUL Stock Holding History

Neo Ivy Capital Management’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-160,389
Closed -$1.95M – 455
2025
Q4 		$1.95M Buy
+160,389
New +$1.95M 0.31% 120

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Neo Ivy Capital Management's OCUL Position: Q1 2026 in Review

Neo Ivy Capital Management sold out of Ocular Therapeutix (OCUL) in Q1 2026, closing a stake of 160,389 shares — an estimated $1.95M sold.

Neo Ivy Capital Management first reported a position in OCUL in Q4 2025 and held it in 1 quarter. The position peaked at $1.95M in Q4 2025. 271 funds tracked by Wall St. Rank hold OCUL as of Q1 2026.

  • Neo Ivy Capital Management reported no remaining Ocular Therapeutix position as of Q1 2026 after selling out during the quarter.
  • Neo Ivy Capital Management sold 160,389 Ocular Therapeutix shares in Q1 2026, an estimated $1.95M.
  • Neo Ivy Capital Management first reported a position in Ocular Therapeutix in Q4 2025 and held it in 1 quarter.
  • Neo Ivy Capital Management's Ocular Therapeutix position peaked at $1.95M in Q4 2025.
  • 271 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q1 2026.

Based on Neo Ivy Capital Management's 13F filing for Q1 2026, filed 15 May 2026.